Elsevier

Clinical Therapeutics

Volume 23, Issue 10, October 2001, Pages 1603-1614
Clinical Therapeutics

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

https://doi.org/10.1016/S0149-2918(01)80132-6Get rights and content

Abstract

Background: Hypersensitivity reactions consist of a variable group of clinical findings and have been described for a wide variety of chemical compounds.

Objective: This review characterizes the clinical profile of hypersensitivity to the nucleoside reverse transcriptase inhibitor abacavir sulfate.

Methods: We performed a retrospective medical review of pooled adverse events data from ∼200,000 patients who received abacavir in clinical trials, through expanded-access programs, or by prescription from 1996 through 2000. Screened cases of hypersensitivity were classified as either definitive or probable. Definitive cases were identified when initial symptoms resolved on interruption of abacavir therapy and returned on reintroduction of abacavir therapy.

Results: A total of 1803 cases were identified, 1302 in the 30,595 patients participating in clinical trials or the expanded-access program and 501 in patients from the postmarketing experience. On review, 176 (9.8%) of these cases were considered definitive and the remainder probable. Based on the 1302 cases identified in clinical trials or the expanded-access program, the calculated incidence of hypersensitivity was 4.3%. Symptoms reported in ≥20% of cases of this multiorgan reaction included fever, rash, malaise/fatigue, and gastrointestinal symptoms such as nausea, vomiting, and diarrhea, among others. Respiratory symptoms occurred in 30% of cases and included dyspnea (12%), cough (10%), and pharyngitis (6%). In 90% of cases, hypersensitivity reactions occurred within the first 6 weeks after initiation of abacavir (median time, 11 days); after an initial reaction, rechallenge with abacavir resulted in the reappearance of symptoms within hours of reexposure. Hypotension was present in 25% of these rechallenge reactions. Among patients who received abacavir in clinical trials, the mortality rate was 0.03% (3 per 10,000 patients).

Conclusions: Hypersensitivity to abacavir is an idiosyncratic reaction and a distinct clinical syndrome characterized predominantly by systemic involvement. It can be expected to appear as a treatment-limiting event in ∼5% of patients. The appearance of clinical symptoms consistent with this syndrome mandates immediate discontinuation of abacavir. Hypersensitivity to abacavir is an absolute contra-indication to subsequent treatment with any formulation that includes this agent.

References (37)

  • S Staszewski et al.

    A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

    AIDS

    (1998)
  • A Cutrell et al.

    Risk factor analysis for hypersensitivity reactions to abacavir

    1st IAS International Symposium on HIV Pathogenesis and Treatment

    (June 8–11, 2001)
  • LE Shapiro et al.

    Mechanisms of drug reactions: The metabolic track

    Sem Cutaneous Med Surg

    (1996)
  • RD deShazo et al.

    Allergic reactions to drugs and biologic agents

    JAMA

    (1997)
  • BK Park et al.

    Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective

    Chem Res Toxicol

    (1998)
  • LR Pohl et al.

    The immunologic and metabolic basis of drug hypersensitivities

    Annu Rev Pharmacol Toxicol

    (1988)
  • M Wassef et al.

    Hypersensitivity to zidovudine: Report of a case of anaphylaxis and review of the literature

    Clin Infect Dis.

    (1995)
  • Y Bourezane et al.

    DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy

    Clin Infect Dis

    (1998)
  • Cited by (383)

    • HIV nucleoside reverse transcriptase inhibitors

      2022, European Journal of Medicinal Chemistry
    • Pharmacogenetics and personalized medicine

      2021, Clinical DNA Variant Interpretation: Theory and Practice: A Volume in Translational and Applied Genomics
    View all citing articles on Scopus

    Presented in part at the 7th Conference on Retroviruses and Opportunistic Infections; January 31–February 2, 2000; San Francisco, California.

    View full text